Jose Cobiella, PA
Internal Medicine · Homestead, FLNPI 1023228988
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,190 of the $1,887 with a category attached, or 63.0%. Janssen Research & Development, LLC accounts for 63.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $1,618 and has fallen 98.8% since, to $20 in 2025.
Across 36 payments — averaging $52.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Novartis$130
- Pfizer$122
- Abbott$85
- E.r. Squibb & Sons, L.L.C.$75
- AstraZeneca$57
- plus $228 from 8 others
Across 152 payments — averaging $22,137 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exeltis, USA Inc.$1.3M
- Braintree Laboratories, Inc.$1.1M
- Mylan Inc.$479K
- Boehringer Ingelheim International GmbH$289K
- Ionis Pharmaceuticals, Inc.$143K
- Amgen$66K
- plus $19K from 3 others
What the payments were for
- Travel & lodging$1,19063%
- Food & beverage$69737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 2 | $1,190 |
| Novartis | 6 | $130 |
| Pfizer | 5 | $122 |
| Abbott | 4 | $85 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| AstraZeneca | 3 | $57 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$1,190
How this compares
$1,887 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $112,497 |
| FarxigaDapagliflozin Propanediol | 87 | $76,770 |
| TrulicityDulaglutide | 32 | $39,569 |
| JardianceEmpagliflozin | 34 | $30,119 |
| EntrestoSacubitril/Valsartan | 14 | $26,144 |
| MounjaroTirzepatide | 23 | $24,234 |
| TradjentaLinagliptin | 32 | $23,458 |
| OzempicSemaglutide | 24 | $23,394 |
| VascepaIcosapent Ethyl | 63 | $22,770 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $17,132 |
| LinzessLinaclotide | 21 | $16,945 |
| JanuviaSitagliptin Phosphate | 18 | $16,517 |
| Etravirine | 11 | $11,565 |
| JentaduetoLinagliptin/Metformin Hcl | 16 | $10,484 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $112,497132 claims |
| AstraZenecaFarxiga, Symbicort | $57 | $84,283115 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $20 | $63,80355 claims |
| NovartisEntresto | $130 | $26,14414 claims |
| MerckJanuvia, Janumet | $17 | $23,96734 claims |
| Novo NordiskOzempic | $19 | $23,39424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Homestead
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.